Paul Clark
Chairman of the Board
Mr. Clark has served as an operating partner of Genstar Capital since July 2007. Prior to joining Genstar, he served as a director, Chief Executive Officer and President of ICOS Corporation from June 1999 until January 2007 and as Chairman of the Board of Directors of ICOS from February 2000 to January 2007. From 1984 to December 1998, Mr. Clark worked in various capacities for Abbott Laboratories, retiring from Abbott as Executive Vice President and as a board member. He previously served as Abbott’s Senior Vice President from 1990 to 1998 and as Vice President from 1984 to 1990. Prior to joining Abbott, he served as Vice President in sales and marketing positions with Marion Laboratories from 1983 to 1984 and in various sales, marketing and operations positions at Sandoz Pharmaceuticals from 1973 to 1983. He currently serves on the board of directors for Agilent Technologies, Inc., Catalent Pharma Solutions, Harlan Labs, Amylin, Talecris Biotherapeutics, Inc. and is on the Board of Overseers of the Amos Tuck School, Dartmouth College. Mr. Clark has extensive experience in the pharmaceutical and biotechnology industries, including serving in senior management and sales and marketing positions. Mr. Clark has extensive experience leading companies in drug discovery, development and commercialization. Mr. Clark received his M.B.A. from Dartmouth College and his B.S. in finance from the University of Alabama.
Gerald McMorrow
Director
Gerald McMorrow is the CEO, Founder and Chairman of the Board of Verathon (formerly Diagnostic Ultrasound Corporation). Since establishing the company in 1984, McMorrow has led Verathon through its transformation from a small start-up venture to an international medical device corporation. Verathon develops and manufactures the BladderScan® at its U.S. headquarters in Bothell, WA and the GlideScope® at its Canadian office in Burnaby, BC. Verathon distributes BladderScan and GlideScope worldwide via its own domestic sales force and a network of international distributors and sales offices. In June 2006, McMorrow was named winner of the Ernst & Young Entrepreneur Of The Year® Award in the Pacific Northwest for the Health Services category. Ernst & Young’s Entrepreneur Of The Year Award program recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses. McMorrow was drafted to serve in Vietnam at the age of 18. As a Vietnam veteran, McMorrow worked his way through school with the aid of the G.I. Bill. McMorrow has Bachelor’s and Master’s degrees cum laude in Electrical Engineering from the University of Washington, Seattle. McMorrow began his career as an engineer at Tektronix, Inc., and subsequently worked at Fluke Corporation, Wavetek, OPCON Inc., Lawrence Medical Systems and Summation Inc., before founding Verathon.
Bradford A. Zakes
Director
Mr. Zakes has spent over 20 years in various segments of the drug and medical device development industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes joined Hazleton Laboratories as a Toxicologist where he designed and managed pre-clinical toxicology studies in support of pharmaceutical products. Mr. Zakes was subsequently hired by Glaxo (currently Glaxo Smithkline) where he initially played a key role in the development of the company’s first US-based toxicology testing facility. While at Glaxo, Mr. Zakes also played an active role in the clinical development of Zantac and managed the sNDA program for the approval of Serevent for chronic obstructive pulmonary disease. Mr. Zakes was a Director at InSite Clinical trials, which was sold to United Healthcare and later served as the President of Heart Research Centers International (HRCI), a wholly owned operating company of MedCath, Inc. Mr. Zakes served as Director of Business Management at ICOS Corporation and President and Chief Executive Officer at ImaRx Therapeutics, a publicly traded biopharmaceutical company. Currently, Mr. Zakes serves as the Chief Executive Officer of Cerevast Therapeutics, a medical technology company focused on the development of new treatments for acute ischemic stroke and other vascular disorders. Mr. Zakes holds a BS degree in Biology from Oregon State University, An MS degree in Toxicology from the American University and received his MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors for the Biotechnology Industry Organization (BIO) as well as the Emerging Company Section Governing Body and the Standing Committees on International Affairs and Budget and Audit for BIO.